Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma
Head & Neck · 2025-07 · 47 (7) · 1996-2002
DOI: 10.1002/hed.28123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, online erschienen am 25.02.2025. Verfasst von Fredrik Jäwert und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic, Head and Neck Neoplasms, Promoter Regions, Genetic, Proto-Oncogene Proteins c-myb. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Swedish state under an agreement between the Swedish government and country councils - the ALF agreement, Stiftelsen Assar Gabrielssons Fond, Cancerfonden.
Abstract (Originalsprache)
Background
Adenoid cystic carcinoma (ACC) is an aggressive therapy‐resistant head and neck cancer with a high frequency of local recurrences and distant metastases. Activation of the MYB gene, encoding an oncogenic master transcription factor, is the key genomic hallmark of ACC and a potential therapeutic target. Here, we have investigated the clinical significance of alternative MYB promoter ( MYB TSS2) activation in primary ACCs.
Methods
MYB TSS2 activity was studied in 28 ACCs using MYB exon‐specific qPCR assays. Overall survival (OS) and risk analyses were done to estimate the outcomes of MYB TSS2 high and low cases, respectively. The genomic and transcriptomic profiles of the ACCs were also analyzed in relation to MYB TSS2 activity.
Results
OS was significantly shorter among patients in the MYB TSS2 high group compared to the MYB TSS2 low group ( p = 0.02). Multivariate analysis indicated that MYB TSS2 activity was a significant prognostic biomarker for OS ( p = 0.03) that was independent of tumor grade and NOTCH1 mutation status. There was markedly higher MYB TSS2 activity in ACCs with 6q deletions compared to those without deletions ( p = 0.04). Moreover, MYB TSS2 high tumors had an increased expression of cell cycle genes and known MYB target genes.
Conclusion
The study demonstrates that alternative MYB promoter activity is a new potential prognostic biomarker for ACC and further strengthens the relevance of MYB‐targeted therapy. Our findings indicate that MYB TSS2 high primary tumors are more aggressive and have a worse prognosis than MYB TSS2 low tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, University of Gothenburg, Gothenburg, Sweden.
- Department of Otorhinolaryngology, Oral and Maxillofacial Surgery, Region Västra Götaland, NU-Hospital Group, Trollhättan, Sweden.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Mattias K Andersson
Förderung
- The Swedish state under an agreement between the Swedish government and country councils - the ALF agreement
- Stiftelsen Assar Gabrielssons Fond
- Cancerfonden
- The Sjöberg Foundation
- Sjöbergstiftelsen
Zitieren
APA
Jäwert, F., Fehr, A., Persson, M., El-Naggar, A. K., Stenman, G., & Andersson, M. K. (2025). Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma. Head & Neck, 47(7), 1996-2002. https://doi.org/10.1002/hed.28123
Vancouver
Jäwert F, Fehr A, Persson M, El-Naggar AK, Stenman G, Andersson MK. Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma. Head & Neck. 2025;47(7):1996-2002. doi:10.1002/hed.28123
BibTeX
@article{Jwert2025,
author = {Jäwert, Fredrik and Fehr, André and Persson, Marta and El-Naggar, Adel K and Stenman, Göran and Andersson, Mattias K},
title = {Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma},
journal = {Head & Neck},
year = {2025},
volume = {47},
number = {7},
pages = {1996--2002},
doi = {10.1002/hed.28123}
}
EUVIMED